List of commercially available insulins

Graphs showing relative effectiveness of each insulin analog over time
The relative effectiveness of each insulin analogue over time[1]

Insulin as a medication is sold under many different trade names, which are listed below. A dagger symbol (†) indicates discontinued brands. Different brands of insulin may offer any of the following preparation methods: vials, pens, cartridges, IV bags or inhalers.[2]

All insulin analogues and non-analogue insulins work by enhancing glucose uptake in tissues and reducing glucose production by the liver.[3] Insulin is prescribed for conditions such as type 1 diabetes, type 2 diabetes,[4] gestational diabetes,[5] and diabetes-related complications such as diabetic ketoacidosis.[6] Additionally, insulin is administered alongside glucose to treat elevated blood potassium levels (hyperkalemia).[7]

While all types are commonly referred to as insulin, the term in its strictest sense applies to the naturally occurring molecule, whereas insulin analogues have modified structures to alter their pharmacokinetics.[8]

Certain insulin brands can also have differing names regionally, such as how Novolog is called Novorapid outside of the United States.[9][10] Brands may also be commonly referred to with different names. For example, Basaglar, Abasaglar, and Abasria all refer to the same brand. Abasria is the brand's former name,[11] while Basaglar and Abasaglar are regional.[11][12][13]

The three companies which produce the most insulin are Lilly, Novo Nordisk and Sanofi. These corporations control 99% of the global market by value and 96% by volume.[14] However, other smaller pharmaceutical companies also produce insulin, such as Mannkind (Afrezza), Viatris (Semglee), Lupin (Lupisulin), Baxter (Myxredlin), Biocon (Basalog), Darou Pakhsh (Dipisulin), Glenmark (Insulong), Wockhardt (Wosulin), Julphar (Jusline), SciGen (SciLin), Bioton (Gensulin), and Cadila (Humanext). Many insulin analogues are available unbranded.[15][16]

Rapid-acting

Insulin lispro

Main article: Insulin lispro
3D model of a protein structure with green and yellow helices spiraling around a central sphere
Insulin lispro hexamer

Insulin lispro, marketed under the brand name Humalog among others, is a modified form of medical insulin used to treat both type 1 and type 2 diabetes.[17] It is administered subcutaneously through injection or an insulin pump.[18][19] The effects typically begin within 30 minutes and last for about 5 hours.[17] Sometimes, a longer-acting insulin, such as insulin NPH, is also used.[20]

Common side effects include low blood sugar, while more serious side effects may include low blood potassium.[21] It is generally considered safe for use during pregnancy and breastfeeding.[22][23] It functions similarly to human insulin by increasing glucose uptake in tissues and reducing the amount of glucose produced by the liver in gluconeogenesis.[24]

Insulin lispro was first approved for use in the United States in 1996.[18][25][26] It is a synthetic analogue of human insulin, created by swapping two amino acids.[27] In 2022, it ranked as the 70th most commonly prescribed medication in the United States, with over 9 million prescriptions.[28][29] Insulin lispro is available under a generic label from Lilly.[30]

Insulin lispro brands
Brand Name Manufacturer Preparation method(s) Image References
Admelog Sanofi Vial, pen vial of admelog insulin [31][32]
Humalog Lilly Vial, cartridge, pen vial of Humalog insulin buried in sugar [33][34]
Liprolog Lilly Vial, cartridge pen [35][36]
Lyumjev Lilly Vial, pen [37]

Insulin aspart

A diagram illustrating the structural formula of insulin aspart. The image consists of a sequence of amino acids represented as orange ovals, labeled with their respective three-letter abbreviations. The structure follows the A and B chains of insulin, with disulfide bonds indicated by connecting lines. Specific modifications, such as the substitution of proline (Pro) at position B28 with aspartic acid (Asp), are highlighted
Structural formula of insulin aspart
Insulin brands usually do not have true logos, and most packaging design is simple
Main article: Insulin aspart

Insulin aspart, marketed under the brand name Novolog among others, is a modified type of medical insulin used to treat both type 1 and type 2 diabetes.[38] It is typically administered by injection under the skin (into the abdomen, buttocks, thighs, or upper arms), but can also be injected into a vein.[39] Its maximum effect occurs after about 1–3 hours and lasts for 3–5 hours.[40] A biosimilar version of insulin aspart, insulin-aspart-szjj, was released in 2025.[41]

Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the injection site. Serious side effects may include low blood potassium.[38] It is generally considered safe to use during pregnancy and breastfeeding.[42][38] It works similarly to human insulin by enhancing glucose uptake in tissues and reducing glucose production by the liver.[38] It is a synthetic form of human insulin, with a single amino acid change, replacing proline with aspartic acid at the B28 position.[43]

Insulin aspart was approved for medical use in the United States in 2000.[44] In 2022, it was the 76th most commonly prescribed medication in the United States, with over 8 million prescriptions.[28][45] Its production involves yeast that have had the gene for insulin aspart inserted into their genome, allowing the yeast to produce the insulin, which is then harvested from the bioreactor.[46][47] Insulin aspart is available unbranded from Novo Nordisk.[15][16]

Insulin aspart brands
Brand Name Manufacturer Preparation method(s) Image References
Fiasp Novo Nordisk Vial, cartridge, pen [48][49]
Novolog/Novorapid Novo Nordisk Vial, cartridge, pen uncapped orange insulin pen labelled Novorapid [50]
Trurapi Sanofi Vial, cartridge, pen [51]
Kirsty Viatris Pen [52][53]
Merilog Sanofi Pen [54][55]

Insulin glulisine

Main article: Insulin glulisine
Box of Apidra SoloStar insulin pens and an uncapped pen in front
Apidra pen and box
model of a protein structure with green helices spiraling around a central sphere
A model of insulin glulisine

Insulin glulisine is a rapid-acting modified form of insulin used to treat diabetes. It differs from human insulin by replacing the amino acid asparagine at position B3 with lysine and the lysine at position B29 with glutamic acid.[56] When injected subcutaneously, it enters the bloodstream faster than regular human insulin (RHI).[57] It was developed by Sanofi. The most common side effect is hypoglycemia (low blood glucose levels).[58]

Insulin glulisine was approved for medical use in the United States[59][60] and the European Union in 2004.[61] It is currently patented by Sanofi, and is therefore only produced by said company under the brand name Apidra.[62]

Inhalable insulin

Main article: Inhalable insulin

Inhalable insulin, also known as technosphere insulin,[63] is a powdered form of insulin, delivered with an inhaler into the lungs where it is absorbed.[64] In general, inhaled insulins have been more rapidly absorbed than subcutaneous injected insulin, with faster peak concentration in serum and more rapid metabolism.[65]

Exubera, developed by Inhale Therapeutics (later named Nektar Therapeutics), became the first inhaled insulin product to be marketed, in 2006 by Pfizer, but poor sales led Pfizer to withdraw it in 2007.[66] Afrezza, a monomeric inhaled, ultra rapid-acting insulin developed by Mannkind, was approved by the FDA in 2014[67] and is the only inhaled insulin commercialized as of 2025.[68]

Inhalable insulin brands
Brand Name Manufacturer Preparation method(s) References
Afrezza Mannkind Inhaler [69][70]
Exubera† Pfizer Inhaler [66]

Short-acting

Regular insulin

Main article: Regular insulin
Circa 1924 black-and-white photo of two men in suits seated in an office, with bookshelves and framed documents in the background
Photograph of Charles Best and Frederick Banting, the inventors of insulin
Insulin monomer model
Insulin monomer

Regular insulin, also known as neutral insulin or soluble insulin, is a type of short-acting medical insulin.[71] It is used to treat type 1 diabetes, type 2 diabetes, gestational diabetes, and complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states.[72] It is also used with glucose to treat high blood potassium levels.[73] Typically administered by injection under the skin, it can also be injected into a vein or muscle.[71] Its effects usually begin within one hour and last around four hours.[74]

The most common side effect is low blood sugar.[72] Other side effects may include pain or skin changes at the injection sites, low blood potassium, and allergic reactions.[75] It is relatively safe to use during pregnancy for the baby.[76] Regular insulin can be derived from the pancreas of pigs or cows, with human versions created by modifying pig insulin or using recombinant technology.[71]

Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922.[77] It is listed on the World Health Organization's List of Essential Medicines.[78] In 2017, it ranked as the 209th most commonly prescribed medication in the United States, with over 2 million prescriptions.[79] There are also versions available that are mixed with longer-acting insulin, such as NPH insulin.[71] In 2020, the combination of human insulin and insulin isophane was the 246th most commonly prescribed medication in the US, with more than 2 million prescriptions.[28][80]

Regular insulin is commonly sold under the name of an insulin product line followed by the letter R.[81]

Regular insulin brands
Brand Name Manufacturer Preparation method(s) Image References
Humulin R Lily Vial, pen a vial labelled humalin R [82][81]
Novolin R Novo Nordisk Vial [83]
Myxredlin Baxter IV bags [84][85]
Insuman R† Sanofi Vial, pen [86][87][88]
Ronulin R Ronak Vial [89]
Lupisulin R Lupin Vial, cartridge [90][91]
Actrapid Novo Nordisk Vial, cartridge, pen a cartridge labelled Actrapid containing a clear liquid [92][93]
Insugen R Biocon Vial, cartridge [94]
Monotard† Novo Nordisk Vial [95][96]
Dipisulin R Darou Pakhsh Vial [97]
Huminsulin R Lupin Vial [98]
Human Insulong Glenmark Vial [99]
Univia R Pfizer Vial [100]
Wosulin R Wockhardt Vial [101]
Jusline R Julphar Vial [102]
Gensulin R Bioton Cartridge [103]
SciLin R SciGen Vial, cartridge [104]

Semilente insulin

Semilente insulin was an insulin from the lente family of insulin that was derived from pork.[105] It had smaller crystals than untralente, so it was absorbed faster, and therefore had a shorter duration of action which was similar to that of regular insulin.[106] Like the other lente insulins, it was phased out in the early 2000s.[107] It was produced by Lilly under the name Semilente Iletin I.[108]

Buffered regular insulin

An insulin pump, which no longer requires specialized insulin

Buffered regular insulin is a variation of regular insulin that is specifically formulated for use only in insulin pumps.[109][110][111]

Buffered regular insulin brands
Brand Name Manufacturer Preparation method(s) References
Humulin BR† Lilly Vial [112][110]
Velosulin BR† Novo Nordisk Vial [112][113]

Intermediate-acting

NPH insulin

Main article: NPH insulin

NPH insulin, also known as isophane insulin, is an intermediate-acting insulin used to manage blood sugar levels in individuals with diabetes. The name NPH is an abbreviation for "neutral protamine Hagedorn", referring to neutral pH (pH = 7), protamine a protein attached to the insulin molecule, and Hans Christian Hagedorn, the insulin researcher who developed this formulation.[114] It was designed to enhance insulin delivery and is one of the early examples of engineered drug delivery.[114]

It is typically administered through subcutaneous injection once or twice daily.[114] Its effects usually begin within an hour and last for 24 hours.[115] There are versions available that are premixed with short-acting insulins, such as regular insulin.[71] The most common side effect is low blood sugar (hypoglycemia). Other potential side effects may include pain or skin changes at the injection sites, low blood potassium, and allergic reactions.[115] It is generally considered safe for use during pregnancy for the fetus.[115][76] NPH insulin is produced by mixing regular insulin and protamine in precise proportions with zinc and phenol to maintain a neutral pH and form crystals. There are versions based on human and pig insulin.[114]

Protamine insulin was first created in 1936, and NPH insulin was introduced in 1946.[114] It is included in the World Health Organization's List of Essential Medicines[78] In 2020, insulin isophane was the 221st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[28][114]

NPH insulin is commonly sold under the name of an insulin product line followed by the letter N.[116]

two vials on a table
Vials
a cartridge containing a clear liquid
Cartridges
two medicine pens
Pens
Insulins can come in varying preparation methods, depending on the brand. These include vials, pens, cartridges, inhalers, and IV bags.
NPH insulin brands
Brand Name Manufacturer Preparation method(s) Image References
Novolin N Novo Nordisk Vial, pen [117][116]
Humulin N Lilly Vial, pen [118]
Insulatard Novo Nordisk Vial, pen An uncapped injector pen labelled Insulatard [119][120]
Insuman Basal† Sanofi Vial, pen [86][87][88]
Actraphane Novo Nordisk Vial, pen [121][122]
Ronulin N Ronak Vial [123]
Lupisulin N Lupin Vial, Cartridge [124]
Insugen N Biocon Vial, Cartridge [125]
Dipusulin N Darou Pakhsh Vial a syringe with an orange cap laying on a table next to a vial with a green label [97]
Huminsulin N Lupin Vial [126][98]
Humanext N Cadila Vial [127]
Wosulin N Wockhardt Vial [128]
Lentard Novo Nordisk Vial [129][130]
Jusline N Julphar Vial [102]
Gensulin N Bioton Cartridge [103]
SciLin N SciGen Vial, cartridge [104]
Protaphane Novo Nordisk Vial [131][132][133]

Lente insulin

Main article: Lente insulin
Insulin hexamer model with multiple colors
Insulin hexamer with a cetral zinc atom (lente)

Lente insulin (derived from the Italian word lento, meaning "slow"), also known as insulin zinc suspension, was an intermediate-acting insulin that is no longer used in humans.[107] Its effects begin one to two hours after administration, with peak activity occurring approximately 8 to 12 hours post-injection, and some residual effects lasting beyond 24 hours.[134]

Manufacturers discontinued Lente insulin and other similar insulin analogs in the mid-2000s, and it is no longer approved for human use in the United States.[135][136][137] This decision was partly due to the medical community's preference for more predictable insulin formulations, such as recombinant NPH insulin.[138]

Similarly to the modern brands of NPH and regular insulin, which are still sold, lente insulins would be marketed under the name of the rest of the insulins in a brand's product line, followed by the letter L.[139]

Lente insulin brands
Brand Name Manufacturer Preparation method(s) References
Humulin L† Lilly Vial, cartridge [139]
Novolin L† Novo Nordisk Vial, cartridge [140]
Iletin† Lilly Vial [141][142]

Long-acting

Insulin detemir

Main article: Insulin detemir
3D molecular structure of insulin detemir, displaying two symmetrical protein chains with color-coded secondary structures, including helices and beta sheets, against a black background
Structure of insulin detemir
clear glass tube labelled Levemir
Levemir PenFill cartridge

Insulin detemir is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes.[143] It is administered through subcutaneous injection. Its effects last for up to 24 hours.[143][144]

Common side effects include (hypoglycemia, allergic reactions, pain at the injection site, and weight gain.[143] It appears to be safe for use during pregnancy and breastfeeding.[145][146] Insulin detemir works by increasing the amount of glucose absorbed by tissues and reducing the amount of glucose produced by the liver.[143]

Insulin detemir was approved for medical use in the European Union in June 2004 and in the United States in June 2005.[147][144][148] It is listed on the World Health Organization's List of Essential Medicines.[78] In 2022, it was the 127th most commonly prescribed medication in the United States, with over 4 million prescriptions.[28][149]

Insulin detemir is only sold under the name Levemir by Novo Nordisk, who owned its patent until 2019. in certain countries, Levemir and certain related products were discontinued in 2024.[150]

Insulin glargine

Main article: Insulin glargine

Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes.[151] It is administered through subcutaneous injection. Its effects typically begin within an hour of injection.[151][152]

Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain.[151] NPH insulin is generally preferred over insulin glargine during pregnancy.[153] After injection, microcrystals gradually release insulin over a period of approximately 24 hours.[151] This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver.[154]

Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000.[152] It is listed on the World Health Organization's List of Essential Medicines.[78] In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions.[28][155] In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes.[156] Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi[157] and Viatris.[158]

Insulin Glargine brands
Brand Name Manufacturer Preparation method(s) Image References
Basaglar/Abasaglar/Abasria Lilly Pen An injector pen labelled Basaglar on a wooden table [159][160]
Lantus Sanofi Vial, cartridge, pen [2]
Toujeo Sanofi Pen an uncapped Toujeo injector pen sitting in front of its box and cap [161][162]
Semglee Viatris Vial, pen [156]
Rezvoglar Lilly Pen [163][158]
Basalog Biocon Vial, pen [164][165]
Optisulin Sanofi Vial, pen [166]

Ultralente insulin

Main article: Ultralente insulin

Ultralente insulin was a long-acting form of medical insulin, but not a true analogue. It had an onset of 4 to 6 hours, a peak effect between 14 and 24 hours, and a duration of 28 to 36 hours.[167] In the mid-2000s, ultralente insulin, along with lente insulin, was discontinued in the United States due to decreasing use in favor of NPH insulin and newer insulin products.[168] By 2011, the U.S. Food and Drug Administration (FDA) had officially withdrawn approval for ultralente insulin products.[169]

Ultralente insulin brands
Brand Name Manufacturer Preparation method(s) References
Ultratard HM† Novo Nordisk Vial [170]
Humulin U† Lilly Vial [171]

Ultralong-acting

Insulin degludec

Main article: Insulin degludec
Space-filling model of an insulin degludec hexamer with lime green representing the A chain, tan representing the B chain, and teal representing the central zinc atom
An insulin degludec hexamer. A chains are chartreuse, B chains are tan, and the central zinc atom is teal.
box with an insulin pen on it labeled degludec
Generic insulin degludec box

Insulin degludec is an ultralong-acting basal insulin analogue developed by Novo Nordisk.[172] Ultralong-acting insulins are a kind of insulin that can work up to a week.[173] It is administered through subcutaneous injection to assist in controlling blood sugar levels in individuals with diabetes. Its duration of action lasts up to 42 hours, which is significantly longer than other long-acting insulins, such as insulin glargine and insulin detemir, which typically last 18 to 26 hours. This makes insulin degludec a once-daily basal insulin,[174][175][176] providing a steady insulin level, in contrast to fast-acting bolus insulins. Insulin degludec is a modified form of insulin in which a single amino acid is deleted compared to human insulin. It is also conjugated to hexadecanedioic acid via a gamma-L-glutamyl spacer at the amino acid lysine at position B29.[175]

It is included on the World Health Organization's List of Essential Medicines[78] as an alternative to insulin glargine. In 2022, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[28][177] Insulin Degludec is currently only produced by Novo Nordisk under the name Tresiba.[172] It is also available under a generic label until the start of 2026.[15]

Insulin icodec

Main article: Insulin icodec

Insulin icodec is a medication used to enhance glycemic control in individuals with diabetes.[178] It is an ultralong-acting basal insulin analogue developed by Novo Nordisk.[179] The analog has a plasma half-life exceeding eight days, which is significantly longer than the 25-hour half-life of insulin degludec, the previously longest-acting insulin analogue. Insulin icodec functions as a once-weekly basal insulin.[178]

graph showing release lengths of insulin analogues
Pharmacokinetic comparison between daily insulins and once weekly icodec insulin

Structurally, insulin icodec consists of two peptide chains connected by a disulfide bridge, similar to insulin. However, it includes a C20 fatty diacid-containing side chain to enable strong, reversible albumin binding. Additionally, three amino acid substitutions enhance molecular stability, reduce insulin receptor binding, and slow clearance, collectively extending its duration of action.[180]

Insulin icodec received approval for medical use in Canada in March 2024.[179] In the same month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion, recommending marketing authorization for insulin icodec.[178] Subsequently, insulin icodec was approved for medical use in the European Union in May 2024.[180] Insulin icodec is currently marketed by Novo Nordisk under the name Awiqli (pronounced A-week-ly).[181]

Insulin mixtures

See also: Combination drug

General mixtures

Insulin mixtures can sometimes be combined in a single syringe, such as when mixing intermediate-acting insulin with rapid- or short-acting insulin. However, not all types of insulin are compatible for mixing.[182][183]

For convenience, there are premixed formulations of rapid- and intermediate-acting insulins.[2] These come in fixed ratios like 75/25, 70/30, or 50/50.[183] For example, a 75/25 mix contains 75% intermediate-acting insulin and 25% rapid-acting insulin.[182][2] These are typically injected twice a day at the start of meals. The mixture appears cloudy, and it begins to work as quickly as the rapid-acting insulin, but it lasts as long as the intermediate-acting insulin.[182]

Branded general mixtures
Brand Name Insulin Concentrations Manufacturer Preparation method(s) Image References
Humalog Mix 75/25 Protamine/lispro (75%/25%) Lilly Vial, pen [2]
Humalog Mix 50/50 Protamine/lispro (50%/50%) Lilly Vial, pen [2]
Lupisulin M 30/70 Regular human/NPH (30%/70%) Lupin Vial, pen [184]
Insugen 50/50 Regular human/NPH (50%/50%) Biocon Vial, cartridge [185]
Insugen 30/70 Regular human/NPH (30%/70%) Biocon Vial, cartridge [186]
Mixtard 30† Regular human/NPH (30%/70%) Novo Nordisk Vial, cartridge, pen clear glass tube labelled Mixtard 30 containing a cloudy white liquid [187]
NovoMix 30 Protamine/aspart (70%/30%) Novo Nordisk Vial, cartridge, pen clear glass tube labelled Novomix 30 containing a cloudy white liquid [2]
Ryzodeg Degludec/aspart (70%/30%) Novo Nordisk Cartridge, pen [188][189][190]
Dipisulin 30/70 Regular human/NPH (30%/70%) Darou Pakhsh Vial [97]
Univia Mix 30/70 Regular human/NPH (30%/70%) Pfizer Vial [191]
Jusline 30/70 Regular human/NPH (30%/70%) Julphar Vial [102]
Gensulin M30 Regular human/NPH (30%/70%) Bioton Cartridge [103]
SciLin M30 Regular human/NPH (30%/70%) SciGen Vial, cartridge [104]

Insulin glargine/lixisenatide

Main article: Insulin glargine/lixisenatide

Insulin glargine/lixisenatide, marketed under the brand name Soliqua,[192] is a fixed-dose combination medication that combines insulin glargine and lixisenatide for the treatment of diabetes.[193] The most common side effects include hypoglycemia, diarrhea, vomiting, and nausea.[194]

Insulin glargine/lixisenatide was approved for medical use in the United States in November 2016, and in the European Union in January 2017.[192] It is currently only marketed by Sanofi as Soliqua.[192]

Insulin degludec/liraglutide

Main article: Insulin degludec/liraglutide
ball and stick model
Ball-and-stick model of liraglutide

Insulin degludec/liraglutide is a fixed-dose combination medication used to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.[195][196][197] It consists of insulin degludec and liraglutide and is administered through subcutaneous injection.[196][197] Gastrointestinal side effects include nausea, diarrhea, vomiting, constipation, dyspepsia (indigestion), gastritis (stomach inflammation), abdominal pain, flatulence, gastroesophageal reflux disease (acid reflux), and abdominal distension.[196][197] Severe symptomatic hypoglycemia was reported in a small number of patients during clinical trials.[197]

Insulin degludec functions as a replacement insulin, facilitating glucose uptake into cells and thereby reducing the symptoms and complications of diabetes.[196][197] It differs slightly from human insulin, as it is absorbed more gradually and consistently, allowing for prolonged action.[196] Liraglutide, a GLP-1 receptor agonist, mimics the effects of incretin hormones by enhancing insulin secretion from the pancreas in response to food intake, thereby aiding blood glucose regulation.[198]

Insulin degludec/liraglutide is sold by Novo Nordisk under the name Xultophy.[199]

Veterinary insulins

General insulins

Insulins that are used mostly in humans are sometimes also used in animals such as cats and dogs.[200] These include Lantus (insulin glargine), Novolin (NPH insulin), Humulin (NPH insulin), and Levemir (Detemir).[201] It is of note that one of the listed insulins other than lente and PZI are FDA-approved for use in animals.[200]

A cat laying on a table while a person administers a shot to it with a thin syringe
A cat receiving an insulin injection

Lente insulin

Main article: Lente insulin

Following the discontinuation of Lente insulin for human use, the FDA approved a veterinary formulation derived from porcine insulin, known as Vetsulin, for daily administration in dogs and twice-daily use in cats.[202] Insulin analogs developed for human use after Lente insulin's discontinuation have not yet been demonstrated to offer the same benefits and predictability in feline and canine patients. For this reason, along with other considerations, Lente insulin remains a widely used treatment for diabetes in both dogs and cats.[203]

Lente insulin is currently produced by Merck Animal Health under the name Vetsulin.[200][202]

PZI insulin (NPH)

Main article: NPH insulin

Protamine zinc insulin (PZI) is the name of a slight variation of NPH insulin that includes zinc, which is similar to lente.[204] It is used for cats and dogs.[205] It is manufactured by Boehringer Ingelheim Animal Health under the name ProZinc.[200]

References

  1. ^ Brateanu, Andrei; Russo-Alvarez, Giavanna; Nielsen, Craig (2015). "Starting insulin in patients with type 2 diabetes: An individualized approach". Cleveland Clinic Journal of Medicine. 82 (8): 513–519. doi:10.3949/ccjm.82a.14069. PMID 26270430. Retrieved 24 February 2025.
  2. ^ a b c d e f g Donnor, Thomas; Sarkar, Sudipa (15 February 2023). "Table 2. Insulins Commercially Available in the US (Recombinant DNA Origin)". United States National Library of Medicine. Retrieved 21 February 2025.
  3. ^ Mathieu, Chantal; Gillard, Pieter; Benhalima, Katrien (July 2017). "Insulin analogues in type 1 diabetes mellitus: getting better all the time". Nature Reviews Endocrinology. 13 (7): 385–399. doi:10.1038/nrendo.2017.39. PMID 28429780.
  4. ^ Sanlioglu, Ahter D.; Altunbas, Hasan Ali; Balci, Mustafa Kemal; Griffith, Thomas S.; Sanlioglu, Salih (March 2013). "Clinical utility of insulin and insulin analogs". Islets. 5 (2): 67–78. doi:10.4161/isl.24590. ISSN 1938-2014. PMC 4204021. PMID 23584214.
  5. ^ Toledano, Yoel; Hadar, Eran; Hod, Moshe (2 July 2016). "Safety of insulin analogues as compared with human insulin in pregnancy". Expert Opinion on Drug Safety. 15 (7): 963–973. doi:10.1080/14740338.2016.1182153. ISSN 1474-0338.
  6. ^ Koufakis, Theocharis; Dhatariya, Ketan K; Kotsa, Kalliopi (28 September 2022). "Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis". The Journal of Clinical Endocrinology and Metabolism. 107 (10): e4259 – e4260. doi:10.1210/clinem/dgac301. ISSN 0021-972X. PMC 9516099. PMID 35552422.
  7. ^ Mahoney, Brian A; Smith, Willard AD; Lo, Dorothy; Tsoi, Keith; Tonelli, Marcello; Clase, Catherine (20 April 2005). "Emergency interventions for hyperkalaemia". Cochrane Database of Systematic Reviews. 2016 (9). Wiley: CD003235. doi:10.1002/14651858.cd003235.pub2. ISSN 1465-1858. PMC 6457842. PMID 15846652.
  8. ^ Hirsch, Irl B. (13 January 2005). "Insulin Analogues". New England Journal of Medicine. 352 (2): 174–183. doi:10.1056/NEJMra040832. ISSN 0028-4793. PMID 15647580.
  9. ^ Reynolds, Neil A; Wagstaff, Antona J (2004). "Insulin Aspart". Drugs. 64 (17). Springer Science and Business Media LLC: 1957–1974. doi:10.2165/00003495-200464170-00013. ISSN 0012-6667. PMID 15329046.
  10. ^ "Novorapid patient information sheet for FlexTouch®/Penfill®/vial" (PDF). Novo Nordisk. September 2020. Archived from the original (PDF) on 27 February 2025.
  11. ^ a b "Abasaglar (previously Abasria)". European Medicines Agency. 14 October 2014. Retrieved 23 February 2025.
  12. ^ Byrd, Richard A.; Owens, Rebecca A.; Blackbourne, Jamie L.; Coutant, David E.; Farmen, Mark W.; Michael, M. Dodson; Moyers, Julie S.; Schultze, A. Eric; Sievert, Michael K.; Tripathi, Niraj K.; Vahle, John L. (August 2017). "Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union". Regulatory Toxicology and Pharmacology. 88: 56–65. doi:10.1016/j.yrtph.2017.05.013. ISSN 1096-0295. PMID 28526658.
  13. ^ "Abasaglar® (insulin glargine): How use the KwikPen". Lilly Medical. Retrieved 2 March 2025.
  14. ^ Beran, D.; Laing, R. O.; Kaplan, W.; Knox, R.; Sharma, A.; Wirtz, V. J.; Frye, J.; Ewen, M. (7 April 2019). "A perspective on global access to insulin: a descriptive study of the market, trade flows and prices". Diabetic Medicine. 36 (6): 726–733. doi:10.1111/dme.13947. ISSN 0742-3071. PMC 6593686. PMID 30888075.
  15. ^ a b c "Unbranded Biologics Insulin Degludec, Insulin Aspart, and Insulin Aspart Mix | Novo Nordisk Pharma, Inc". nnpi.com. Retrieved 2 March 2025.
  16. ^ a b "Novo Nordisk announces half-price, authorized generic insulins". Healio News. Retrieved 2 March 2025.
  17. ^ a b Islam, Noreen; Khanna, Niloufar R.; Patel, Preeti; Zito, Patrick M. (2025), "Insulin Lispro", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29939617, retrieved 26 March 2025
  18. ^ a b "Insulin Lispro Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  19. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 1 October 2018. p. 698. ISBN 9780857113382.
  20. ^ Vignati, Louis; Anderson, James H.; Iversen, Philip W. (November 1997). "Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non—insulin-dependent diabetes mellitus". Clinical Therapeutics. 19 (6): 1408–1421. doi:10.1016/S0149-2918(97)80014-8.
  21. ^ Racsa, Patrick N.; Meah, Yunus; Ellis, Jeffrey J.; Saverno, Kimberly R. (March 2017). "Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes". Journal of Managed Care & Specialty Pharmacy. 23 (3): 291–298. doi:10.18553/jmcp.2017.23.3.291. ISSN 2376-0540. PMC 10397578. PMID 28230457.
  22. ^ "Insulin lispro Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 19 September 2020. Retrieved 3 March 2019.
  23. ^ Buchbinder, A.; Miodovnik, M.; Khoury, J.; Sibai, B. M. (April 2002). "Is the use of insulin lispro safe in pregnancy?". The Journal of Maternal-Fetal & Neonatal Medicine. 11 (4): 232–237. doi:10.1080/jmf.11.4.232.237. ISSN 1476-7058. PMID 12375676.
  24. ^ Heinemann, Lutz; Beals, John M.; Malone, James; Anderson, James; Jacobson, Jennie G.; Sinha, Vikram; Corrigan, Sheila M. (April 2019). "Concentrated insulins: History and critical reappraisal". Journal of Diabetes. 11 (4): 292–300. doi:10.1111/1753-0407.12861. ISSN 1753-0393. PMID 30264527.
  25. ^ "Humalog- insulin lispro injection, solution Humalog Kwikpen- insulin lispro injection, solution Humalog Junior Kwikpen- insulin lispro injection, solution Humalog Tempo Pen- insulin lispro injection, solution". DailyMed. 25 November 2019. Archived from the original on 24 September 2019. Retrieved 23 February 2020.
  26. ^ "Humalog approval" (PDF). Food and Drug Administration. 14 June 1996. Archived from the original (PDF) on 24 February 2020. Retrieved 23 February 2020.
  27. ^ Koivisto VA (June 1998). "The human insulin analogue insulin lispro". Annals of Internal Medicine. 30 (3): 260–6. doi:10.3109/07853899809005853. PMID 9677011.
  28. ^ a b c d e f g "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  29. ^ "Insulin Lispro Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  30. ^ "Lilly's Insulin Lispro Injection (100 units/mL) | Lower List-Priced Insulin". Lilly Medical. Retrieved 2 March 2025.
  31. ^ "FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes". Food and Drug Administration. 24 March 2020. Retrieved 23 February 2025.[dead link]
  32. ^ "Diabetes Treatment | Diabetes Type 1 & 2 | ADMELOG® (insulin lispro injection) 100 Units/mL". admelog.com. Retrieved 31 March 2025.
  33. ^ "Humalog® (insulin lispro) injection Family of Insulins". Lilly Medical. Retrieved 23 February 2025.
  34. ^ "Humalog: Uses, Dosage & Side Effects". Drugs.com. Retrieved 23 February 2025.
  35. ^ "Liprolog". European Medicines Agency. 26 September 2009. Retrieved 21 February 2025.
  36. ^ "Official overview of Liprolog (insulin lispro)" (PDF). European Commission. Retrieved 23 February 2025.
  37. ^ "Lyumjev (previously Liumjev)". European Medicines Agency. 16 April 2020. Retrieved 23 February 2025.
  38. ^ a b c d Rubin, Rochelle; Khanna, Niloufar R.; McIver, Lindsey A. (2025), "Aspart Insulin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29763206, retrieved 26 March 2025
  39. ^ Wen, Wei-Lun; Tsai, Kun-Bow; Lin, Yi-Huei; Hwang, Shang-Jyh; Hsiao, Pi-Jung; Shin, Shyi-Jang; Hung, Wei-Wen (April 2019). "Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone". Journal of the Formosan Medical Association. 118 (4): 843–848. doi:10.1016/j.jfma.2019.01.004. PMID 30704815.
  40. ^ Heise, Tim; Pieber, Thomas R.; Danne, Thomas; Erichsen, Lars; Haahr, Hanne (May 2017). "A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes". Clinical Pharmacokinetics. 56 (5): 551–559. doi:10.1007/s40262-017-0514-8. ISSN 0312-5963. PMC 5385193. PMID 28205039.
  41. ^ "FDA Approves First Insulin Aspart Biosimilar". Center for Biosimilars. 17 February 2025. Retrieved 19 February 2025.
  42. ^ "Insulin aspart Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  43. ^ J. Rick, Turner (16 July 2010). New Drug Development: An Introduction to Clinical Trials: Second Edition. Springer Science & Business Media. p. 32. ISBN 9781441964182. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
  44. ^ "Insulin Aspart Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  45. ^ "Insulin Aspart Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  46. ^ Banga, Ajay K. (2005). Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems (2nd ed.). CRC Press. p. 13. ISBN 9781420039832. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
  47. ^ Schmid, Rolf D.; Schmidt-Dannert, Claudia (2016). Biotechnology: An Illustrated Primer. John Wiley & Sons. p. 222. ISBN 9783527677566. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
  48. ^ "Fiasp® Official Physician Site | Fiasp® (insulin aspart) injection 100 U/mL". novoMEDLINK. Retrieved 23 February 2025.
  49. ^ "Fiasp prescribing information" (PDF). FDA accessdata. December 2019. Archived from the original (PDF) on 3 August 2020.
  50. ^ "About NovoLog® Rapid-Acting Insulin | NovoLog® (insulin aspart) injection 100 U/mL". novolog.com. Retrieved 23 February 2025.
  51. ^ "Trurapi® ▾". Sanofi Diabetes Patients Website. Retrieved 23 February 2025.
  52. ^ "KIRSTY (Insulin asparte) 100 U/mL pre-filled pen". Diabetes Express. Retrieved 5 March 2025.
  53. ^ "Introducing Kirsty and Semglee, the Newest Biosimilar Insulin Products Available in Canada". BETTER. 24 December 2022. Retrieved 5 March 2025.
  54. ^ "Merilog: Package Insert / Prescribing Information". Drugs.com. Retrieved 11 March 2025.
  55. ^ "FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes". FDA. 18 February 2025. Archived from the original on 14 February 2025. Retrieved 11 March 2025.
  56. ^ Home, P. D. (September 2012). "The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences". Diabetes, Obesity and Metabolism. 14 (9): 780–788. doi:10.1111/j.1463-1326.2012.01580.x. ISSN 1462-8902. PMID 22321739.
  57. ^ Garnock-Jones, Karly P.; Plosker, Greg L. (May 2009). "Insulin glulisine: a review of its use in the management of diabetes mellitus". Drugs. 69 (8): 1035–57. doi:10.2165/00003495-200969080-00006. PMID 19496630. S2CID 41839395.
  58. ^ Yamada, Satoru (July 2009). "Insulin glulisine in the management of diabetes". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy: 111. doi:10.2147/DMSOTT.S3404. ISSN 1178-7007. PMC 3048006. PMID 21437124.
  59. ^ "Apidra- insulin glulisine injection, solution; Apidra Solostar- insulin glulisine injection, solution". DailyMed. 25 July 2023. Retrieved 10 August 2024.
  60. ^ "Drug Approval Package: Apidra (Insulin Glulisine [rDNA Origin]) NDA #021629". Food and Drug Administration. Archived from the original on 5 April 2015. Retrieved 10 August 2024.
  61. ^ "Apidra EPAR". European Medicines Agency. 27 July 2009. Retrieved 7 October 2020.
  62. ^ US20150119323A1, Loos, Petra; Gehrmann, Thomas & Berchtold, Harald et al., "Stable Formulation of Insulin Glulisine", issued 30 April 2015  | via Google Patents
  63. ^ Jarosinski, Mark A; Chen, Yen-Shan; Varas, Nicolás; Dhayalan, Balamurugan; Chatterjee, Deepak; Weiss, Michael A (24 November 2021). "New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals". The Journal of Clinical Endocrinology and Metabolism. 107 (4): 909–928. doi:10.1210/clinem/dgab849. ISSN 0021-972X. PMC 8947325. PMID 34850005.
  64. ^ Neumiller, Joshua J; Campbell, R Keith; Wood, Lindy D (July 2010). "Pharmacologist". Annals of Pharmacotherapy. 1231–9 (44): 1231–1239. doi:10.1345/aph.1P055. PMID 20516362.
  65. ^ McGill JB, Ahn D, Edelman SV, Kilpatrick CR, Santos Cavaiola T (August 2016). "Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?". Advances in Therapy. 33 (8): 1267–78. doi:10.1007/s12325-016-0370-1. PMID 27384191. S2CID 25390720.
  66. ^ a b Heinemann, Lutz (May 2008). "The Failure of Exubera: Are We Beating a Dead Horse?". Journal of Diabetes Science and Technology. 2 (3): 518–529. doi:10.1177/193229680800200325. PMC 2769732. PMID 19885220.
  67. ^ Brashier, Dick; Khadka, Anjan; Anantharamu, Tejus; Sharma, Ashok Kumar; Gupta, A. K.; Sharma, Sushil; Dahiya, N. (July 2015). "Inhaled insulin: A "puff" than a "shot" before meals". Journal of Pharmacology and Pharmacotherapeutics. 6 (3): 126–129. doi:10.4103/0976-500X.162013. PMC 4544132. PMID 26311994.
  68. ^ "FDA approves Afrezza to treat diabetes" (News Release). Food and Drug Administration. 27 June 2014. Archived from the original on 6 July 2014. Retrieved 19 July 2016.
  69. ^ "Take Control with Afrezza® Rapid-acting Inhaled Insulin". Afrezza. Retrieved 23 February 2025.
  70. ^ "MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes". MannKind Corporation. 27 June 2014.
  71. ^ a b c d e Joint Formulary Committee (6 March 2015). British National Formulary : BNF 69 (69th ed.). London and Chicago: Pharmaceutical Press. p. 464472. ISBN 9780857111562.
  72. ^ a b Dave, Heeransh D.; Preuss, Charles V. (2025), "Human Insulin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31424774, retrieved 16 March 2025
  73. ^ Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM (April 2005). "Emergency interventions for hyperkalaemia". The Cochrane Database of Systematic Reviews. 2005 (2): CD003235. doi:10.1002/14651858.CD003235.pub2. PMC 6457842. PMID 15846652.
  74. ^ Munguia, Cesar; Correa, Ricardo (2025), "Regular Insulin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31971734, retrieved 26 March 2025
  75. ^ Ghazavi MK, Johnston GA (May–June 2011). "Insulin allergy". Clinics in Dermatology. 29 (3): 300–5. doi:10.1016/j.clindermatol.2010.11.009. PMID 21496738.
  76. ^ a b Subiabre M, Silva L, Toledo F, Paublo M, López MA, Boric MP, Sobrevia L (September 2018). "Insulin therapy and its consequences for the mother, foetus, and newborn in gestational diabetes mellitus". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864 (9 Pt B): 2949–2956. doi:10.1016/j.bbadis.2018.06.005. hdl:10533/232608. PMID 29890222. S2CID 48362789.
  77. ^ Fleishman, Joel L; Kohler, J Scott; Schindler, Steven (2007). Casebook for The Foundation a Great American Secret. New York City: PublicAffairs. p. 22. ISBN 978-0-7867-3425-2. Archived from the original on 18 January 2017.
  78. ^ a b c d e WHO Model List of Essential Medicines - 22nd list, 2021 Retrieved 31 March 2025, World Health Organization 2021
  79. ^ "Insulin Human - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
  80. ^ "Insulin Human; Insulin Isophane Human - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  81. ^ a b "Humulin R, Novolin R (insulin regular human) dosing, indications, interactions, adverse effects, and more". Medscape. Retrieved 23 February 2025.
  82. ^ "A1C & Diabetes Treatment Options | Humulin R U-500". Lilly Medical. Retrieved 23 February 2025.
  83. ^ "Novolin R prescription label and use instructions" (PDF). Novo Nordisk. Archived from the original (PDF) on 18 February 2017. Retrieved 23 February 2025.
  84. ^ "Myxredlin (Insulin Human) in 0.9% Sodium Chloride Injection". Baxter International. Retrieved 28 February 2025.
  85. ^ "Myxredlin Uses, Side Effects & Warnings". Drugs.com. Retrieved 28 February 2025.
  86. ^ a b "Insuman". European Medicines Agency. 11 June 2009. Retrieved 23 February 2025.
  87. ^ a b "Insuman® range discontinuation and supply exhaustion update | The Association of British Clinical Diabetologists". abcd.care. Retrieved 23 February 2025.
  88. ^ a b "Sanofi to discontinue Insuman insulins over upcoming months". IDDT. Retrieved 23 February 2025.
  89. ^ "Ronulin R". شرکت داروسازی روناک. Retrieved 5 March 2025.
  90. ^ "LUPISULIN-R 40 IU INJECTION - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 5 March 2025.
  91. ^ "Lupisulin-R 100 IU Cartridge - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 5 March 2025.
  92. ^ "Actrapid: Uses, Side Effects, Benefits/Risks". Drugs.com. Retrieved 23 February 2025.
  93. ^ "Actrapid human insulin fact sheet" (PDF). European Medicines Agency. Retrieved 23 February 2025.
  94. ^ "Insugen-R 40IU Injection - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 5 March 2025.
  95. ^ "Monotard". European Medicines Agency. 15 February 2008. Retrieved 5 March 2025.
  96. ^ "EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) MONOTARD. EPAR summary for the public" (PDF). European Medicines Agency. January 2006. Retrieved 3 March 2025.
  97. ^ a b c "Iranian Pharmaceutical Companies Directory" (PDF). Embassy of the Islamic Republic of Iran - The Hague. Syndicate of Iranian Pharmaceutical Industries. 2022. Retrieved 3 April 2025.
  98. ^ a b "Lupin Acquires Huminsulin from Lilly to Enhance Diabetes Portfolio". Lupin. 30 December 2024. Retrieved 5 March 2025.
  99. ^ "Human Insulong 40 IU Injection - Uses, Dosage, Side Effects, Price, Composition | Practo". Practo. Retrieved 5 March 2025.
  100. ^ "Univia R 40IU/ml Injection - Niche Formulations". Retrieved 5 March 2025.
  101. ^ "Wosulin-R: Dosages and Ingredients | Full Prescribing Info | MIMS Philippines". MIMS. Retrieved 6 March 2025.
  102. ^ a b c "Insulin". Julphar. Retrieved 7 March 2025.
  103. ^ a b c "Gensulin N, M, R cartridges | BIOTON | CPHI Online". cphi-online.com. Retrieved 7 March 2025.
  104. ^ a b c "GENSULIN / SciLin | SciGen Pte Ltd | CPHI Online". cphi-online.com. Retrieved 7 March 2025.
  105. ^ Hallas-Mø, K (1 January 1956). "The Lente Insulins". Diabetes. 5 (1): 7–14. doi:10.2337/diab.5.1.7. ISSN 0012-1797. PMID 13294001.
  106. ^ Shiel, Robert E.; Mooney, Carmel T. (14 February 2022). "Insulins for the long term management of diabetes mellitus in dogs: a review". Canine Medicine and Genetics. 9 (1) 1. doi:10.1186/s40575-022-00114-9. ISSN 2662-9380. PMC 8842735. PMID 35152907.
  107. ^ a b Holmberg, Monica (1 October 2006). "An Overview of Insulin Breakthroughs". Pharmacy Times. Vol. 2006, no. 10. Pharmacy & Healthcare Communications. Retrieved 11 May 2020.
  108. ^ Institution, Smithsonian. "U-100 S, Semilente Iletin I, Prompt Insulin Zinc Suspension, USP, 10cc, CP-510". Smithsonian Institution. Retrieved 5 March 2025.
  109. ^ "Insulin (parenteral route)". Mayo Clinic. Retrieved 5 March 2025.
  110. ^ a b "Humulin BR, Buffered Regular, insulin human injection, USP, recombinant DNA origin". Smithsonian Institution. Retrieved 5 March 2025.
  111. ^ Campbell, Keith R. (September 1986). "Humulin BR, A New Insulin for Use in External Insulin Pumps". The Diabetes Educator. 12 (4): 392. doi:10.1177/014572178601200411. ISSN 0145-7217.
  112. ^ a b Olsen, Anders; Beall, Reed F.; Knox, Ryan P.; Tu, Sean S.; Kesselheim, Aaron S.; Feldman, William B. (16 November 2023). "Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019". PLOS Medicine. 20 (11): e1004309. doi:10.1371/journal.pmed.1004309. ISSN 1549-1676. PMC 10653475. PMID 37971985.
  113. ^ "Velosulin BR Side Effects: Common, Severe, Long Term". Drugs.com. Retrieved 5 March 2025.
  114. ^ a b c d e f Owens DR (1986). Human Insulin: Clinical Pharmacological Studies in Normal Man. Springer Science & Business Media. pp. 134–136. ISBN 9789400941618. Archived from the original on 18 January 2017.
  115. ^ a b c Saleem, Fatima; Sharma, Ashish (2025), "NPH Insulin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 31751050, retrieved 16 March 2025
  116. ^ a b "Insulin NPH (Humulin N, Novolin N): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing". WebMD. Retrieved 23 February 2025.
  117. ^ "Novolin N: Uses, Side Effects, Dosage & More". GoodRx. Archived from the original on 24 November 2024. Retrieved 23 February 2025.
  118. ^ "HUMULIN N Dosage & Rx Info | Uses, Side Effects". MPR. Retrieved 23 February 2025.
  119. ^ "Insulatard". European Medicines Agency. 6 August 2008. Retrieved 23 February 2025.
  120. ^ March 2020 Insulatard Patient leaflet, from Novo Nordisk (accessed February 23, 2025)
  121. ^ Colagiuri, S.; Jones, S. (December 1988). "Comparison of the activity of Rapitard and Actraphane insulins". Diabète & Métabolisme. 14 (6): 689–692. ISSN 0338-1684. PMID 3073090.
  122. ^ "Actraphane: Uses, Side Effects, Benefits/Risks". Drugs.com. Retrieved 31 March 2025.
  123. ^ "Ronulin N". شرکت داروسازی روناک. Retrieved 5 March 2025.
  124. ^ "Order Lupisulin N 100iu Cartridge Of 3ml Injection Online at discount rate". pharmeasy.in. Retrieved 5 March 2025.
  125. ^ Insugen NPH facsheet, Biocon, December 2019
  126. ^ "Huminsulin N 40 IU Injection". Practo. Retrieved 5 March 2025.
  127. ^ "Humanext-N 40 IU Injection - Uses, Dosage, Side Effects, Price, Composition". Practo. Retrieved 5 March 2025.
  128. ^ "Wosulin-N: Dosages and Ingredients | Full Prescribing Info | MIMS Philippines". MIMS. Retrieved 6 March 2025.
  129. ^ "Lentard 40 IU Injection - Uses, Dosage, Side Effects, Price, Composition". Practo. Retrieved 6 March 2025.
  130. ^ Wing, J. R.; Kalk, W. J.; Herman, V. S.; Constable, J.; Osler, C. E.; Taylor, D. R.; Green, D. D.; Low, M. (20 August 1988). "Actraphane and Lentard insulin for once daily insulin supplementation". South African Medical Journal. 74 (4): 191. ISSN 0256-9574. PMID 3043728.
  131. ^ "About the discontinuation of Protaphane InnoLet insulin cartridges". Department of Health and Aged Care. 4 February 2025. Retrieved 7 March 2025.
  132. ^ "Types of Insulin". Diabetes New Zealand. Retrieved 7 March 2025.
  133. ^ "Protaphane: Uses, Side Effects, Benefits/Risks". Drugs.com. Retrieved 7 March 2025.
  134. ^ Owens, David R. (June 2011). "Insulin Preparations with Prolonged Effect". Diabetes Technology & Therapeutics. 13 (S1): S-5 – S-14. doi:10.1089/dia.2011.0068. PMID 21668337.
  135. ^ Federal Register Doc. E9-2901
  136. ^ Federal Register Doc. 2011-14164
  137. ^ List of Withdrawn Applications for Biological Products That Were Removed From FDA’s Orange Book on March 23, 2020 Food and Drug Administration, retrieved 31 March 2025
  138. ^ "Discontinuation of Humulin®U ULTRALENTE" (PDF). Food and Drug Administration. Archived from the original (PDF) on 1 December 2011. Retrieved 11 May 2020.
  139. ^ a b "Humulin L: Package Insert / Prescribing Information". Drugs.com. Retrieved 5 March 2025.
  140. ^ "Novolin L Side Effects: Common, Severe, Long Term". Drugs.com. Retrieved 5 March 2025.
  141. ^ "Manufactured insulin, 'Iletin', United States, 1923 | Science Museum Group Collection". Science Museum Group. Retrieved 5 March 2025.
  142. ^ "Lilly To Discontinue Four Insulin Products". Lilly Investors. 6 July 2005.
  143. ^ a b c d Philips, Jean-Christophe; Scheen, Andre (August 2006). "Insulin detemir in the treatment of type 1 and type 2 diabetes". Vascular Health and Risk Management. 2 (3): 277–283. doi:10.2147/vhrm.2006.2.3.277. ISSN 1176-6344. PMC 1993987. PMID 17326333.
  144. ^ a b "Insulin Detemir Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  145. ^ Koren, Ronit; Toledano, Yoel; Hod, Moshe (3 April 2015). "The use of insulin detemir during pregnancy: a safety evaluation". Expert Opinion on Drug Safety. 14 (4): 593–599. doi:10.1517/14740338.2015.1013533. ISSN 1474-0338. PMID 25731934.
  146. ^ "Insulin detemir (Levemir) Use During Pregnancy". Drugs.com. 12 June 2019. Retrieved 14 April 2020.
  147. ^ "Levemir EPAR". European Medicines Agency. 6 August 2009. Retrieved 14 April 2020.
  148. ^ "Drug Approval Package: Levemir Insulin Detemir[rDNA origin] Injection; NDA #021536". Food and Drug Administration. 26 July 2005. Archived from the original on 4 April 2015. Retrieved 14 April 2020.
  149. ^ "Insulin Detemir Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  150. ^ Barber, Melissa; Sofides, Athena; Ramachandran, Reshma (12 July 2024). "Counting On Insulin Manufacturers To Do The Right Thing Is Not A Good Policy Prescription To Avert Shortages". Health Affairs. doi:10.1377/forefront.20240710.982244. Retrieved 27 February 2025.
  151. ^ a b c d Cunningham, Abigail M.; Freeman, Andrew M. (2025), "Glargine Insulin", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32491688, retrieved 26 March 2025
  152. ^ a b "Insulin Glargine Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 5 December 2020. Retrieved 23 December 2018.
  153. ^ Egerman, Robert; Ramsey, Risa; Kao, Lu; Bringman, Jay; Haerian, Haleh; Kao, Jerome; Bush, Andrew (September 2009). "Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine". American Journal of Perinatology. 26 (8): 591–595. doi:10.1055/s-0029-1220782. ISSN 0735-1631. PMID 19370512.
  154. ^ Boucher, J.; Kleinridders, A.; Kahn, C. R. (1 January 2014). "Insulin Receptor Signaling in Normal and Insulin-Resistant States". Cold Spring Harbor Perspectives in Biology. 6 (1): a009191. doi:10.1101/cshperspect.a009191. ISSN 1943-0264. PMC 3941218. PMID 24384568.
  155. ^ "Insulin Glargine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  156. ^ a b "FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes". Food and Drug Administration. 30 July 2021. Archived from the original on 28 July 2021. Retrieved 23 February 2025.
  157. ^ "Insulin Glargine u-100 (insulin glargine injection) | From the Makers of Lantus® (insulin glargine injection) 100 Units/mL". lantus.com. Retrieved 2 March 2025.
  158. ^ a b "SEMGLEE - (insulin glargine-yfgn) injection Homepage". semglee.com. Archived from the original on 13 January 2025. Retrieved 2 March 2025.
  159. ^ "Basaglar: Alternatives, side effects, cost, dosage, uses, and more". Medical News Today. 27 July 2019. Retrieved 23 February 2025.
  160. ^ "Basaglar: Side Effects, Dosage & Uses". Drugs.com. Retrieved 23 February 2025.
  161. ^ "Long Acting Insulin To Control Blood Sugar | Toujeo® (insulin glargine) injection 300 Units/mL". toujeo.com. Retrieved 23 February 2025.
  162. ^ "Toujeo SoloStar Uses, Dosage & Side Effects". Drugs.com. Retrieved 23 February 2025.
  163. ^ "Rezvoglar™ (insulin glargine-aglr) injection | Long-Acting Insulin Analog". Lilly Medical. Retrieved 21 February 2025.
  164. ^ "Basalog Injection - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 23 February 2025.
  165. ^ "Basalog One: Dosages and Ingredients | Full Prescribing Info | MIMS Malaysia". mims.com. Retrieved 23 February 2025.
  166. ^ "Optisulin". News-Medical. Retrieved 23 February 2025.
  167. ^ Holman, R R; Steemson, J; Darling, P; Reeves, W G; Turner, R C (3 March 1984). "Human ultralente insulin". BMJ. 288 (6418): 665–668. doi:10.1136/bmj.288.6418.665. ISSN 0959-8138. PMC 1444374. PMID 6421424.
  168. ^ "Discontinuation of Humulin®U ULTRALENTE" (PDF). Eli Lilly and Company. 1 December 2011. Archived from the original (PDF) on 1 December 2011.
  169. ^ "List of Withdrawn Applications for Biological Products That Were Removed From FDA's Orange Book on March 23, 2020". Food and Drug Administration. Archived from the original on 22 December 2020. Retrieved 18 May 2020.
  170. ^ Holman, R R; Steemson, J; Darling, P; Reeves, W G; Turner, R C (3 March 1984). "Human ultralente insulin". BMJ. 288 (6418): 665–668. doi:10.1136/bmj.288.6418.665. PMC 1444374. PMID 6421424.
  171. ^ "Humulin U, ULTRALENTE". National Museum of American History. Retrieved 5 March 2025.
  172. ^ a b "Tresiba® Official Physician Site | Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL". novoMEDLINK. Retrieved 23 February 2025.
  173. ^ Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, Porsgaard T, Fledelius C, Refsgaard HH, Gram-Nielsen S, Naver H, Pridal L, Hoeg-Jensen T, Jeppesen CB, Manfè V, Ludvigsen S, Lautrup-Larsen I, Madsen P (July 2021). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. PMID 33944562. S2CID 233718893.
  174. ^ Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–299. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.
  175. ^ a b Haahr H, Heise T (September 2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.
  176. ^ "Tresiba Summary of product characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 4 March 2016. Retrieved 29 September 2014.
  177. ^ "Insulin Degludec Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  178. ^ a b c Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, Porsgaard T, Fledelius C, Refsgaard HH, Gram-Nielsen S, Naver H, Pridal L, Hoeg-Jensen T, Jeppesen CB, Manfè V, Ludvigsen S, Lautrup-Larsen I, Madsen P (July 2021). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. PMID 33944562. S2CID 233718893.
  179. ^ a b "Product information". Health Canada. Archived from the original on 1 April 2024. Retrieved 26 February 2025.
  180. ^ a b Nishimura E, Pridal L, Glendorf T, Hansen BF, Hubálek F, Kjeldsen T, Kristensen NR, Lützen A, Lyby K, Madsen P, Pedersen TÅ, Ribel-Madsen R, Stidsen CE, Haahr H (August 2021). "Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing". BMJ Open Diabetes Research & Care. 9 (1): e002301. doi:10.1136/bmjdrc-2021-002301. PMC 8378355. PMID 34413118.
  181. ^ "Home: Awiqli". Awiqli.ca. Retrieved 26 February 2025.
  182. ^ a b c "Types of Insulin". Cham.org. Retrieved 23 February 2025.
  183. ^ a b Donnor, Thomas; Sarkar, Sudipa (2000), Feingold, Kenneth R.; Ahmed, S. Faisal; Anawalt, Bradley; Blackman, Marc R. (eds.), "Insulin- Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy", Endotext, South Dartmouth (MA): MDText.com, Inc., PMID 25905175, retrieved 26 March 2025
  184. ^ "Lupisulin-M 30 (30/70) 40 IU Injection - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 24 February 2025.
  185. ^ "Insugen-50/50 40IU Injection - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 5 March 2025.
  186. ^ "Insugen-30/70 100IU Injection - Uses, Dosage, Side Effects, Price, Composition | Practo". practo.com. Retrieved 5 March 2025.
  187. ^ "Discontinuation of Mixtard® 30: Practical considerations". omniamedsso.om-systems.net. Retrieved 23 February 2025.
  188. ^ "Ryzodeg". European Medicines Agency. 20 February 2013. Retrieved 26 February 2025.
  189. ^ Demir T, Turan S, Unluhizarci K, Topaloglu O, Tukek T, Gogas Yavuz D (2021). "Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns". Frontiers in Endocrinology. 12: 616514. doi:10.3389/fendo.2021.616514. PMC 7996092. PMID 33776914.
  190. ^ "Ryzodeg Clinical Datasheet" (PDF). Novo Nordisk. 2023. Retrieved 23 February 2025.
  191. ^ "Buy Univia Mix 30/70 40IU Injection 1X10ml Online at Upto 25% OFF". Netmeds. Retrieved 5 March 2025.
  192. ^ a b c "SOLIQUA 100/33- insulin glargine and lixisenatide injection, solution". DailyMed. Retrieved 23 February 2025.
  193. ^ "Suliqua EPAR". European Medicines Agency. 30 March 2017. Retrieved 10 September 2020.
  194. ^ Scott, Lesley J. (August 2017). "Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes". Drugs. 77 (12): 1353–1362. doi:10.1007/s40265-017-0783-4. ISSN 0012-6667. PMID 28667587.
  195. ^ "Xultophy 100/3.6 (- insulin degludec and liraglutide injection, solution". DailyMed. 15 November 2019. Retrieved 15 May 2020.
  196. ^ a b c d e "Xultophy EPAR". European Medicines Agency. 21 November 2014. Retrieved 30 March 2025.
  197. ^ a b c d e Baker, Danial E. (May 2017). "Insulin Degludec/Liraglutide". Hospital Pharmacy. 52 (5): 374–380. doi:10.1177/0018578717715383. ISSN 0018-5787. PMC 5551637. PMID 28804155.
  198. ^ Cerillo, John L.; Parmar, Mayur (2025), "Liraglutide", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 39383283, retrieved 26 March 2025
  199. ^ "About Xultophy® 100/3.6 (insulin degludec and liraglutide) injection 100 units/mL and 3.6 mg/mL| NovoCare®". novocare.com. Retrieved 26 February 2025.
  200. ^ a b c d "Insulins commonly used in dogs and cats". AAHA. 10 May 2019. Retrieved 24 February 2025.
  201. ^ Hess, Rebecka S.; Drobatz, Kenneth J. (15 October 2013). "Glargine insulin for treatment of naturally occurring diabetes mellitus in dogs". Journal of the American Veterinary Medical Association. 243 (8): 1154–1161. doi:10.2460/javma.243.8.1154. PMID 24094263.
  202. ^ a b "Compendium of Veterinary Products". merckusa.cvpservice.com.
  203. ^ Behrend, Ellen; Holford, Amy; Lathan, Patty; Rucinsky, Renee; Schulman, Rhonda (January 2018). "2018 AAHA Diabetes Management Guidelines for Dogs and Cats". Journal of the American Animal Hospital Association. 54 (1): 4–6. doi:10.5326/JAAHA-MS-6822. PMID 29314873. S2CID 43327430.
  204. ^ Mosenthal, Herman O. (8 January 1938). "PROTAMINE ZINC INSULIN CLINICAL APPLICATION". The Journal of the American Medical Association. 110 (2): 87–90. doi:10.1001/jama.1938.02790020001001.
  205. ^ "Protamine Zinc Insulin for Dogs and Cats - Wedgewood Pharmacy". wedgewood.com. Retrieved 24 February 2025.
Index: pl ar de en es fr it arz nl ja pt ceb sv uk vi war zh ru af ast az bg zh-min-nan bn be ca cs cy da et el eo eu fa gl ko hi hr id he ka la lv lt hu mk ms min no nn ce uz kk ro simple sk sl sr sh fi ta tt th tg azb tr ur zh-yue hy my ace als am an hyw ban bjn map-bms ba be-tarask bcl bpy bar bs br cv nv eml hif fo fy ga gd gu hak ha hsb io ig ilo ia ie os is jv kn ht ku ckb ky mrj lb lij li lmo mai mg ml zh-classical mr xmf mzn cdo mn nap new ne frr oc mhr or as pa pnb ps pms nds crh qu sa sah sco sq scn si sd szl su sw tl shn te bug vec vo wa wuu yi yo diq bat-smg zu lad kbd ang smn ab roa-rup frp arc gn av ay bh bi bo bxr cbk-zam co za dag ary se pdc dv dsb myv ext fur gv gag inh ki glk gan guw xal haw rw kbp pam csb kw km kv koi kg gom ks gcr lo lbe ltg lez nia ln jbo lg mt mi tw mwl mdf mnw nqo fj nah na nds-nl nrm nov om pi pag pap pfl pcd krc kaa ksh rm rue sm sat sc trv stq nso sn cu so srn kab roa-tara tet tpi to chr tum tk tyv udm ug vep fiu-vro vls wo xh zea ty ak bm ch ny ee ff got iu ik kl mad cr pih ami pwn pnt dz rmy rn sg st tn ss ti din chy ts kcg ve
Prefix: a b c d e f g h i j k l m n o p q r s t u v w x y z 0 1 2 3 4 5 6 7 8 9

Portal di Ensiklopedia Dunia

Portal : Agama
Agama
Portal : Bahasa
Bahasa
Portal : Biografi
Biografi
Portal : Budaya
Budaya
Portal : Ekonomi
Ekonomi
Portal : Elektronika
Elektronika
Portal : Film
Film
Portal : Filsafat
Filsafat
Portal : Geografi
Geografi
Portal : Indonesia
Indonesia
Portal : Ilmu
Ilmu
Portal : Lingkungan
Lingkungan
Portal : Masyarakat
Masyarakat
Portal : Matematika
Matematika
Portal : Militer
Militer
Portal : Mitologi
Mitologi
Portal : Musik
Musik
Portal : Olahraga
Olahraga
Portal : Pendidikan
Pendidikan
Portal : Politik
Politik
Portal : Sastra
Sastra
Portal : Sejarah
Sejarah
Portal : Seni
Seni
Portal : Teknologi
Teknologi

Kembali kehalaman sebelumnya